I agree the data is fantastic in that the survival outcomes are durable at 4 years. However, I fail to see why this is important as a cornerstone for the BLA resubmission? The FDA are asking about potency assays and not wondering whether the survival outcomes are long term
I agree the data is fantastic in that the survival outcomes are...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.000(0.00%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2247 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.43 | 6118 | 1 |
View Market Depth
| Last trade - 09.44am 12/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
Day chart unavailable